US regulators turn away Amgen/UCB’s bone drug Evenity

17th July 2017 Uncategorised 0

Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators.

More: US regulators turn away Amgen/UCB’s bone drug Evenity
Source: News